To our knowledge, this is the first study in which the expression levels of ESR2 variants in FAP, adenomatous polyps and sporadic colorectal carcinomas have been evaluated and compared with normal mucosa, tumour stage and prognosis data. The gene discussed is FAP; the disease is neoplasm.